Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men. - Wikidata - wikimedia - TriplyDB

Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men.

Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men.

http://www.wikidata.org/entity/Q34834065

about

Biomarkers and biometric measures of adherence to use of ARV-based vaginal rings Maraviroc: a review of its use in HIV infection and beyond Preventing HIV infection: pre-exposure and postexposure prophylaxis CCR5 antagonism in HIV infection: current concepts and future opportunities Antiretroviral pharmacology in mucosal tissues Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial Immune responses during spontaneous control of HIV and AIDS: what is the hope for a cure?Differential penetration of raltegravir throughout gastrointestinal tissue: implications for eradication and cure.Development and bioanalytical validation of a liquid chromatographic-tandem mass spectrometric (LC-MS/MS) method for the quantification of the CCR5 antagonist maraviroc in human plasma.Expression of six drug transporters in vaginal, cervical, and colorectal tissues: Implications for drug disposition in HIV prevention Pharmacokinetics of antiretrovirals in genital secretions and anatomic sites of HIV transmission: implications for HIV prevention.CYP3A5 genotype impacts maraviroc concentrations in healthy volunteers.Current perspectives in HIV post-exposure prophylaxis.Models for predicting effective HIV chemoprevention in women Concentrations of tenofovir and emtricitabine in saliva: implications for preexposure prophylaxis of oral HIV acquisition.Pharmacokinetic profile of raltegravir, elvitegravir and dolutegravir in plasma and mucosal secretions in rhesus macaques The male genital tract is not a pharmacological sanctuary from efavirenz.Anogenital HIV RNA in Thai men who have sex with men in Bangkok during acute HIV infection and after randomization to standard vs. intensified antiretroviral regimens.A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge.The use of preexposure treatments for HIV prophylaxis HIV prevention by oral preexposure prophylaxis.HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model.Pharmacokinetics of antiretrovirals in mucosal tissue Pharmacodynamic Activity of Dapivirine and Maraviroc Single Entity and Combination Topical Gels for HIV-1 Prevention Single- and multiple-dose pharmacokinetics of darunavir plus ritonavir and etravirine in semen and rectal tissue of HIV-negative men.Does ART prevent HIV transmission among MSM?Antiviral agents and HIV prevention: controversies, conflicts, and consensus.Pre-exposure prophylaxis for HIV prevention: how to predict success.Antiretrovirals and safer conception for HIV-serodiscordant couples Next-generation oral preexposure prophylaxis: beyond tenofovir Lack of prophylactic efficacy of oral maraviroc in macaques despite high drug concentrations in rectal tissues Dolutegravir pharmacokinetics in the genital tract and colorectum of HIV-negative men after single and multiple dosing.Antiretroviral bioanalysis methods of tissues and body biofluids.HIV PrEP Trials: The Road to Success.Pre-exposure prophylaxis for HIV infection: how antiretroviral pharmacology helps to monitor and improve adherence Expression, regulation, and function of drug transporters in cervicovaginal tissues of a mouse model used for microbicide testing.Drug safety evaluation of maraviroc for the treatment of HIV infection.The development of rectal microbicides for HIV prevention.An overview of antiretroviral pre-exposure prophylaxis of HIV infection.Strategies to limit immune-activation in HIV patients.

P2860

Q26753097-9F8AF010-5347-44D5-899B-1743CE8B3DC9 Q26778504-0A8ABA9E-6920-4B27-B9C1-E54E7FC6A2F8 Q26828445-84EF1392-3231-432C-8635-CAAEB8395BD4 Q26865457-5333117B-6D49-483B-B6C4-4CB78E560C2F Q27014675-6CC1F9C1-750B-4CF8-AA48-456C00E453FE Q28552729-C542AE80-9779-4CBD-8409-E676FA3878AE Q30362489-80AEA266-B60B-4E89-A112-AD981554F45A Q33593633-BAE0E9EF-6C2A-4E76-AC2F-D64817BB2C48 Q33643626-86158FBE-FC62-471B-A6E8-E64F7F490B9A Q33769971-77FF0A8D-F46C-46E5-8B2E-0BB4B735A373 Q33888718-CB3BE7D6-5FB6-4636-8576-2CE440B6BF0A Q34360012-BC6E07DF-D7AF-4AE5-85DF-DBCED3FFAE0D Q34434815-CCC77C35-9D57-4B06-ADC0-2E0934BBFD0A Q35102285-579A0BE5-4286-464F-A855-90F0782EA422 Q35270776-C727CD5B-D161-4265-AECD-DF6FF6BCED13 Q35432739-3111C961-FFA7-4A04-96DC-8ED90C436DDE Q35548422-140D10E2-F662-44BA-9557-2C7B9F9B6BEF Q35588077-34C0AF27-18B1-4429-BE2F-E1C1DC0B044A Q35667426-5C4DBE1D-68EE-4D14-87F0-69CE7D1D502C Q35760180-04E902E1-A559-4A54-AC4A-28FFA04E8946 Q35765743-412CDF46-3619-461D-A981-8B3895068256 Q35794988-5CF6CCBB-688F-476F-B7C5-1B40473C6418 Q35838594-7F85778F-A1A8-4133-9AAF-61F25B09851F Q36143276-656F6845-FDD4-425E-B54B-64B044BCA307 Q36279339-30A9B81B-E632-4723-BC24-FB7D5DBD9B9A Q36403679-7663FEDE-17D3-4F52-9A47-01322FE692F7 Q36836680-63714306-284D-49D0-9FC6-A2487EEB28A7 Q36839567-632792F7-691D-4C3D-BE55-C9E68A3BF346 Q36964167-205BEBA3-2DD4-4AA1-8C23-CCA180F9FD43 Q37067126-DB31A3D9-84CB-4EA0-9D34-EE7FABA5EA1C Q37123335-C927328B-EA13-4763-8B36-60767A343DB7 Q37246359-6EAA65A5-0366-40ED-894A-282E99DBA6CD Q37332868-917E41DB-5D08-42D7-86C6-69731EA791B0 Q37438644-72FBA7C9-04C9-472B-97B4-4EA9C629A7E9 Q37637073-96680018-ECDA-4765-9E5A-C0D37672EFDA Q37716218-075C33A0-8F93-4A57-9747-86A6E15BF40E Q37961188-85F2F61D-E356-4F3B-83F6-2EC9FB965AE1 Q38165222-26D103D5-B771-41C3-A329-C927C97CFA68 Q38196410-DDABC9D5-371D-49B8-9418-F798178098C3 Q38985926-3A963BE5-1DBD-4064-A6D2-69343966061A

P2860

Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men.

http://www.wikidata.org/entity/Q34834065

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Single and multiple dose pharm ...... e of healthy HIV-negative men.

@ast

Single and multiple dose pharm ...... e of healthy HIV-negative men.

@en

Single and multiple dose pharm ...... e of healthy HIV-negative men.

@nl

type

label

Single and multiple dose pharm ...... e of healthy HIV-negative men.

@ast

Single and multiple dose pharm ...... e of healthy HIV-negative men.

@en

Single and multiple dose pharm ...... e of healthy HIV-negative men.

@nl

prefLabel

Single and multiple dose pharm ...... e of healthy HIV-negative men.

@ast

Single and multiple dose pharm ...... e of healthy HIV-negative men.

@en

Single and multiple dose pharm ...... e of healthy HIV-negative men.

@nl

P1433

Q34834065-36402B2F-38FB-42BC-84EA-30A7A0B9F5C4

P1476

Q34834065-35AB4A3D-1722-4A85-BEF3-02833E7790BC

P2093

Q34834065-125FD7FC-9AE2-40EF-9374-9B6353B19C05

Q34834065-153079F0-A5E4-49F4-BE59-0F8DA5119EEC

Q34834065-7E9B695A-F9BD-4A48-8740-42A845B91941

Q34834065-88C87F19-9E65-4B75-8C5B-CC3181792D5B

Q34834065-8BA122E9-506C-41DE-9F42-14B999900366

Q34834065-AB0CE174-EEAB-4949-9D95-68E8C6307C23

Q34834065-CF9CD77F-9345-472A-A624-9C84E227DF0B

Q34834065-D87428AF-017D-4892-BBE3-7BA9A3F41561

P2860

Q34834065-0ABB243B-F9EE-412D-96A5-74CBB0097782

Q34834065-12DEC950-39FC-413C-85AB-2E6F04019115

Q34834065-1A6E3969-7A6E-4591-93F9-AC1DDAF92E13

Q34834065-1FAC53A1-7906-430E-9F99-B923A6D91E46

Q34834065-30C73497-7FF9-4F36-AB04-063B5305950C

Q34834065-329C4C85-9C20-4F08-9CBC-969A3E3C5695

Q34834065-3716B201-F180-4300-8143-26FC9A4FF926

Q34834065-6DCE1F0B-3AAC-466A-AA7E-A0333E13F3F5

Q34834065-76100035-7BBF-4508-A95F-59AFD0A54B04

Q34834065-9063FF12-8E27-4465-9DF8-AB4E5A67899F

P304

Q34834065-1CD7AC69-1957-4DAD-827D-D50F5ED94458

P31

Q34834065-88F8DE7B-48DE-46C8-A6F9-87198A701887

P356

Q34834065-37658BF8-D600-41C1-8BEA-C911968E7D1D

P407

Q34834065-C35898F2-0F8A-443D-94BD-BA4AAD3798DA

P433

Q34834065-D97054DB-47F7-4C97-9911-83213D1086AB

P478

Q34834065-8B3D6270-DF91-492A-B39C-717B0746EB57

P50

Q34834065-691CFE32-3C8A-4CD3-AC91-0AD7316097E8

Q34834065-ECE6DF64-F26C-47D8-8EF3-B991E855F498

P577

Q34834065-EAD6213E-CE3B-44CE-95A6-CF72B4D571F9

P5875

Q34834065-61699E21-9C17-47DB-95EB-5B36F062FA43

P698

Q34834065-9C43EE16-94AB-4413-9834-00DA8410E5C3

P932

Q34834065-2B4BA30F-B488-4A4F-94D7-B2708538939D

P356

P1433

The Journal of Infectious Diseases

P1476

Single and multiple dose pharm ...... e of healthy HIV-negative men.

@en

P2093

Angela D M Kashuba

http://www.w3.org/2001/XMLSchema#string

Heather M Asher Prince

http://www.w3.org/2001/XMLSchema#string

Julie B Dumond

http://www.w3.org/2001/XMLSchema#string

Kevin C Brown

http://www.w3.org/2001/XMLSchema#string

Kristine B Patterson

http://www.w3.org/2001/XMLSchema#string

Melissa B Spacek

http://www.w3.org/2001/XMLSchema#string

Paris E Heidt

http://www.w3.org/2001/XMLSchema#string

Stephanie A Malone

http://www.w3.org/2001/XMLSchema#string

P2860

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women

HIV-1 vaccine development after STEP.

Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis

Primary intestinal epithelial cells selectively transfer R5 HIV-1 to CCR5+ cells.

Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.

The use of rectal douches among HIV-uninfected and infected men who have unprotected receptive anal intercourse: implications for rectal microbicides.

Drug transfer through mucus.

The CCR5 and CXCR4 coreceptors--central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection.

Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers.

Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1.

P304

1484-1490

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/INFDIS/JIR059

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

203

http://www.w3.org/2001/XMLSchema#string

P50

Nicholas J Shaheen

P577

2011-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51059853

http://www.w3.org/2001/XMLSchema#string

P698

21502084

http://www.w3.org/2001/XMLSchema#string

P932

3080897

http://www.w3.org/2001/XMLSchema#string